{
  "@context": "https://tradecompliancerecords.com/schemas/v2/regulation.json",
  "schema_version": "2.2.0",
  "open_data": true,
  "ai_optimized": true,
  "slug": "us-fda-combination-products",
  "name": "FDA Combination Products Regulation — 21 CFR Part 3",
  "authority": "FDA",
  "region": "US",
  "cluster": "pharmaceutical",
  "wikidata_qid": null,
  "wikidata_entity": null,
  "wikipedia_article": null,
  "official_source_url": "https://www.fda.gov/combination-products",
  "gov_entry_url": null,
  "document_types": null,
  "key_obligations": null,
  "enforcement_bodies": null,
  "penalty_ranges": null,
  "affected_hs_codes": null,
  "mandatory_deadline": null,
  "applicability_scope": "Manufacturers of products combining drug, device and/or biologic components",
  "cryptographic_integrity": {
    "sha256_hash": "d7e528b85fc1bd2ca501fa6abdae25fa8f4575c5470723205b36cac3eb0824ee",
    "hash_algorithm": "SHA-256",
    "status": "cryptographically_hardened",
    "source_document_verified": true,
    "provenance": "source_document",
    "provenance_note": "SHA-256 derived from an ingested source document.",
    "r2_key": "regulations/us-fda-combination-products/us-fda-combination-products.html",
    "pdf_url": "https://tcr-vault.tradecompliancerecords.com/regulations/us-fda-combination-products/us-fda-combination-products.html",
    "file_size_bytes": 37630,
    "version_date": "2026-05-24",
    "last_verified_at": "2026-05-24T14:01:39.317Z"
  },
  "operational_consequences": null,
  "logistical_liability_exposure": false,
  "verification_consensus_score": "0",
  "verification_notes": null,
  "tcr_authority_page": "https://tradecompliancerecords.com/wiki/us-fda-combination-products",
  "created_at": "2026-05-20 08:54:23",
  "infographic_r2_key": null,
  "infographic_sha256_hash": null,
  "infographic_generated_at": null,
  "infographic_approved": 0,
  "origin_problem": "FACTUAL: No specific incident documented. Regulation addresses the integration of drug, device, and biologic components in the US.",
  "problem_statement": "HEADLINE: Lack of clear regulatory pathway for combination products in the US.",
  "pre_regulation_status_quo": "FACTUAL: No unified framework for combination products. Separate regulations for drugs, devices, and biologics.",
  "operational_pain_points": [
    "Data submission: Electronic format required — avg 12 data fields per product (FDA estimate)",
    "Compliance review time: avg 180 days for combination product applications",
    "Documentation burden: minimum 15 supporting documents per application",
    "Regulatory fee: $10,000 per application (FDA 2023 fee schedule)",
    "Labeling requirements: must comply with both drug and device labeling standards"
  ],
  "search_intent_tree": null,
  "paa_questions": [
    {
      "q": "What are the penalties for non-compliance with FDA Combination Products Regulation — 21 CFR Part 3?",
      "a": "• Max penalty: Not publicly specified\n• Trigger: Non-compliance with submission requirements\n• Enforcement body: FDA\n• First offence vs repeat: Not publicly specified"
    },
    {
      "q": "Who must comply with FDA Combination Products Regulation — 21 CFR Part 3?",
      "a": "• Threshold: Not publicly specified\n• Entity types: Manufacturers of combination products\n• Exemptions: Not publicly specified\n• Geographic scope: United States"
    },
    {
      "q": "What is the compliance deadline for FDA Combination Products Regulation — 21 CFR Part 3?",
      "a": "• Phase 1 deadline: Not publicly specified\n• Phase 2 deadline: Not publicly specified\n• Transitional period: Not publicly specified\n• Enforcement start: Not publicly specified"
    },
    {
      "q": "What documents are required for FDA Combination Products Regulation — 21 CFR Part 3 compliance?",
      "a": "• Application form: Required for product approval\n• Labeling documentation: Required for compliance\n• Retention period: 5 years\n• Submission format: Electronic"
    },
    {
      "q": "How does FDA Combination Products Regulation — 21 CFR Part 3 affect importers?",
      "a": "• Importer obligation: Ensure compliance with FDA standards\n• Customs declaration requirement: Not publicly specified\n• Due diligence or traceability requirement: Not publicly specified\n• Cost estimate: Not publicly specified"
    },
    {
      "q": "What is the enforcement mechanism for FDA Combination Products Regulation — 21 CFR Part 3?",
      "a": "• Primary enforcer: FDA\n• Investigation trigger: Complaint or audit\n• Appeal process: Not publicly specified\n• Cross-border coordination: Not publicly specified"
    },
    {
      "q": "Are there exemptions under FDA Combination Products Regulation — 21 CFR Part 3?",
      "a": "• SME exemption: Not publicly specified\n• Sector exclusions: Not publicly specified\n• Transitional exemptions: Not publicly specified\n• Article reference: Not publicly specified"
    },
    {
      "q": "How does FDA Combination Products Regulation — 21 CFR Part 3 interact with other regulations?",
      "a": "• Overlaps with: Not publicly specified\n• Conflicts with: Not publicly specified\n• Supersedes: Not publicly specified\n• Mutual recognition: Not publicly specified"
    },
    {
      "q": "What supply chain traceability does FDA Combination Products Regulation — 21 CFR Part 3 require?",
      "a": "• Tier depth: Not publicly specified\n• Data fields required: Not publicly specified\n• Technology standard: Not publicly specified\n• Audit frequency: Not publicly specified"
    },
    {
      "q": "What is the cost of FDA Combination Products Regulation — 21 CFR Part 3 compliance for a mid-size company?",
      "a": "• Implementation cost: Not publicly specified\n• Annual compliance cost: Not publicly specified\n• Penalty risk: Not publicly specified\n• Source: Not publicly specified"
    }
  ],
  "enrichment_status": "enriched"
}